IDEAYA Biosciences Announces Positive Data From Phase 1/2 Combination Trial of IDE397, a potential first-in-class MAT2A inhibitor, and Trodelvy® in MTAP-Deletion Urothelial Cancer
1. IDE397 shows 57% ORR with Trodelvy in late-line cancer patients. 2. Safety profile aligns with known effects of both drugs, no severe events observed. 3. Future updates planned for medical conferences, with Phase 2 dose selection aimed for 2025. 4. Three patients showed confirmed responses; trial suggests better outcomes than Trodelvy alone. 5. MTAP-deletion occurs in 25-30% of UC patients, with no existing FDA-approved treatments.